In May 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between Janssen and the Division of Medical Ethics at New York University (NYU) Langone Health to form the Compassionate Use Advisory Committee (CompAC).
CompAC is a novel approach that Johnson & Johnson employs globally to provide a fair, ethical evaluation of compassionate use requests for specific investigational medicines for patients with serious or life-threatening diseases.
Below, watch these two videos to learn more about the Compassionate Use Advisory Committee (CompAC).
Below is an infographic (English only) illustrating the key results from Janssen’s first CompAC pilot program. Click here to open this infographic as a PDF.
Compassionate Use & Pre-Approval Access
Compassionate Use & Pre-Approval Access
